The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Alessenko A.V.

Institute of Biochemical Physic of the Russian Academy of Sciences

Gutner U.A.

Institute of Biochemical Physic of the Russian Academy of Sciences

Nebogatikov V.O.

Institute of Physiologically Active Compounds of the Russian Academy of Sciences

Shupik M.A.

Institute of Biochemical Physic of the Russian Academy of Sciences

Ustyugov A.A.

Institute of Physiologically Active Compounds of the Russian Academy of Sciences

The role of lipids in the pathogenesis of lateral amyotrophic sclerosis

Authors:

Alessenko A.V., Gutner U.A., Nebogatikov V.O., Shupik M.A., Ustyugov A.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(10): 108‑117

DOI: 10.17116/jnevro2020120101108

Read: 5623 times

Contact the author
Table of contents

THE ROLE OF LIPIDS IN THE PATHOGENESIS OF LATERAL AMYOTROPHIC SCLEROSIS
THE ROLE OF LIPIDS IN THE PATHOGENESIS OF LATERAL AMYOTROPHIC SCLEROSIS

To cite this article:

Alessenko AV, Gutner UA, Nebogatikov VO, Shupik MA, Ustyugov AA. The role of lipids in the pathogenesis of lateral amyotrophic sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(10):108‑117. (In Russ.)
https://doi.org/10.17116/jnevro2020120101108

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Lipid profile indi­cators and their ratios in patients with non-ST elevation acute coro­nary syndrome. Russian Cardiology Bulletin. 2025;(3):48-53
Oppo­rtunities of combination therapy for chro­nic liver diseases: resu­lts of the multicenter PROMETHEUS study. Russian Journal of Evidence-Based Gastroenterology. 2025;(3):56-68
Comprehensive asse­ssment of students’ health based on the resu­lts of examinations at the health center. Russian Journal of Preventive Medi­cine. 2025;(12):76-82
Abstract:

Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease characterized by selective degeneration of motor neurons of the motor cortex, brain stem and brain stem. Mutations in genes coding for SOD1, C9ORF72, TDP-43, FUS and others are associated with ALS and result in abnormal processing and transport of RNA as well as changes in the dynamics of cytoskeleton. In addition, a sharp change in the metabolism of various lipid classes, including phospholipids, fatty acids, sphingolipids, etc., was detected. This review describes changes in lipid content and activity of enzymes involved in their metabolism in ALS animal models as well as in patients. Changes in the metabolism of fatty acids, phospholipids, cholesterol and its derivatives are reviewed in detail. The prospects of searching for new drugs among modulators of lipid metabolism enzymes are discussed.

Keywords:

amyotrophic lateral sclerosis (ASA)
ALS models
lipids
fatty acids
phospholipids
cholesterol

Authors:

Alessenko A.V.

Institute of Biochemical Physic of the Russian Academy of Sciences

Gutner U.A.

Institute of Biochemical Physic of the Russian Academy of Sciences

Nebogatikov V.O.

Institute of Physiologically Active Compounds of the Russian Academy of Sciences

Shupik M.A.

Institute of Biochemical Physic of the Russian Academy of Sciences

Ustyugov A.A.

Institute of Physiologically Active Compounds of the Russian Academy of Sciences

Received:

08.11.2019

Accepted:

10.04.2020

Close metadata

References:

  1. Van Den Bosch L. Genetic rodent models of amyotrophic lateral sclerosis. J Biomed Biotechnol. 2011;348765. https://doi.org/10.1155/2011/348765
  2. Robberecht W, Sapp P, Viaene MK, Rosen D, McKenna-Yasek D, Haines J, Horvitz R, Theys P, Brown R Jr. Cu/Zn superoxide dismutase activity in familial and sporadic amyotrophic lateral sclerosis. J Neurochem. 1994;62(1):384-387.  https://doi.org/10.1046/j.1471-4159.1994.62010384.x
  3. Koppers M, van Blitterswijk MM, Vlam L, Rowicka PA, van Vught PW, Groen EJ, Spliet WG, Engelen-Lee J, Schelhaas HJ, de Visser M, van der Kooi AJ, van der Pol WL, Pasterkamp RJ, Veldink JH, van den Berg LH. VCP mutations in familial and sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33:837.  https://doi.org/10.1016/j.neurobiolaging.2011.10.006
  4. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, Kinoshita Y, Kamada M, Nodera H, Suzuki H, Komure O, Matsuura S, Kobatake K, Morimoto N, Abe K, Suzuki N, Aoki M, Kawata A, Hirai T, Kato T, Ogasawara K, Hirano A, Takumi T, Kusaka H, Hagiwara K, Kaji R, Kawakami H. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223-226.  https://doi.org/10.1038/nature08971
  5. Daoud H, Suhail H, Szuto A, Camu W, Salachas F, Meininger V, Bouchard JP, Dupré N, Dion PA, Rouleau GA. UBQLN2 mutations are rare in French and French-Canadian amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33(2):2230-2233. https://doi.org/10.1016/j.neurobiolaging.2012.03.015
  6. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung GY, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245-256.  https://doi.org/10.1016/j.neuron.2011.09.011
  7. Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, Kwong LK, Forman MS, Ravits J, Stewart H, Eisen A, McClusky L, Kretzschmar HA, Monoranu CM, Highley JR, Kirby J, Siddique T, Shaw PJ, Lee VM, Trojanowski JQ. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007;61:427-434.  https://doi.org/10.1002/ana.21147
  8. Kwiatkowski TJ, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205-1208. https://doi.org/10.1126/science.1166066
  9. Deng HX, Zhai H, Bigio EH, Yan J, Fecto F, Ajroud K, Mishra M, Ajroud-Driss S, Heller S, Sufit R, Siddique N, Mugnaini E, Siddique T. FUS-immunoreactive inclusions are a common feature in sporadic and nonSOD1 familial amyotrophic lateral sclerosis. Ann Neurol. 2010;67:739-748.  https://doi.org/10.1002/ana.22051
  10. Daoud H, Dobrzeniecka S, Camu W, Meininger V, Dupré N, Dion PA, Rouleau GA. Mutation analysis of PFN1 in familial amyotrophic lateral sclerosis patients. Neurobiol Aging. 2013;34(4):1311.e1-e2.  https://doi.org/10.1016/j.neurobiolaging.2012.09.001
  11. Münch C, Sedlmeier R, Meyer T, Homberg V, Sperfeld AD, Kurt A, Prudlo J, Peraus G, Hanemann CO, Stumm G, Ludolph AC. Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology. 2004;63(4):724-726.  https://doi.org/10.1212/01.WNL.0000134608.83927.B1
  12. Rademakers R, van Blitterswijk M. Excess of rare damaging TUBA4A variants suggests cytoskeletal defects in ALS. Neuron. 2014;84(2):241-243.  https://doi.org/10.1016/j.neuron.2014.10.002
  13. Ghasemi M, Brown RH. Genetics of amyotrophic lateral sclerosis. Cold Spring Harb Perspect Med. 2017;7:a024125. https://doi.org/10.1101/cshperspect.a024125
  14. Van Damme P, Dewil M, Robberecht W, Van Den Bosch L. Excitotoxicity and Amyotrophic Lateral Sclerosis. Neurodegener Dis. 2005;2(3-4):147-159.  https://doi.org/10.1159/000089620
  15. Shi P, Gal J, Kwinter DM, Liu X, Zhu H. Mitochondrial dysfunction in amyotrophic lateral sclerosis. Biochim Biophys Acta. 2010;1802(1):45-51.  https://doi.org/10.1016/j.bbadis.2009.08.012
  16. Chitnis T, Weiner HL. CNS inflammation and neurodegeneration. J Clin Invest. 2017;127(10):3577-3587. https://doi.org/10.1172/JCI90609
  17. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;14(3):CD001447. https://doi.org/10.1002/14651858.CD001447.pub3
  18. Bhandari R, Kuhad A, Kuhad A. Edaravone: a new hope for deadly amyotrophic lateral sclerosis. Drugs Today (Barc). 2018;54(6):349-360.  https://doi.org/10.1358/dot.2018.54.6.2828189
  19. Peters OM, Ghasemi M, Brown RH Jr. Emerging mechanisms of molecular pathology in ALS. J Clin Invest. 2015;125(5):1767-1779. https://doi.org/10.1172/jci71601
  20. Ripps ME, Huntley GW, Hof PR, Morrison JH, Gordon JW. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 1995;92(3):689-693.  https://doi.org/10.1073/pnas.92.3.689
  21. Bowling AC, Schulz JB, Brown RH Jr, Beal MF. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem. 1993;61(6):2322-2325. https://doi.org/10.1111/j.1471-4159.1993.tb07478.x
  22. McCombe PA, Henderson RD. The Role of Immune and Inflammatory Mechanisms in ALS. Curr Mol Med. 2011;11(3):246-254.  https://doi.org/10.2174/1566211213754895240
  23. D’Amico E, Factor-Litvak P, Santella RM, Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med. 2013;65:509-527.  https://doi.org/10.1016/j.freeradbiomed.2013.06.029
  24. Nagase M, Yamamoto Y, Miyazaki Y, Yoshino H. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. Redox Rep. 2016;21(3):104-112.  https://doi.org/10.1179/1351000215Y.0000000026
  25. Boillée S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312(5778):1389-1392. https://doi.org/10.1126/science.1123511
  26. Philips T, Rothstein JD. Glial cells in amyotrophic lateral sclerosis. Exp Neurol. 2014;262 Pt B:111-120.  https://doi.org/10.1016/j.expneurol.2014.05.015
  27. Ozdinler PH, Benn S, Yamamoto TH, Güzel M, Brown RH Jr, Macklis JD. Corticospinal motor neurons and related subcerebral projection neurons undergo early and specific neurodegeneration in hSOD1G9³A transgenic ALS mice. J Neurosci. 2011;31(11):4166-4177. https://doi.org/10.1523/JNEUROSCI.4184-10.2011
  28. Hatzipetros T, Bogdanik LP, Tassinari VR, Kidd JD, Moreno AJ, Davis C, Osborne M, Austin A, Vieira FG, Lutz C, Perrin S. C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS. Brain Res. 2014;1584:59-72.  https://doi.org/10.1016/j.brainres.2013.10.013
  29. Joyce PI, Fratta P, Fisher EM, Acevedo-Arozena A. SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments. Mamm Genome. 2011;22(7-8):420-448.  https://doi.org/10.1007/s00335-011-9339-1
  30. Kang SH, Li Y, Fukaya M, Lorenzini I, Cleveland DW, Ostrow LW, Rothstein JD, Bergles DE. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat Neurosci. 2013;16(5):571-579.  https://doi.org/10.1038/nn.3357
  31. Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model ofamyotrophic lateral sclerosis. Neurobiology of disease. 2002;10:268-278.  https://doi.org/10.1006/nbdi.2002.0487
  32. Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport. 2002;13:1067-1070. https://doi.org/10.1097/00001756-200206120-00018
  33. Philips T, Bento-Abreu A, Nonneman A, Haeck W, Staats K, Geelen V, Hersmus N, Küsters B, Van Den Bosch L, Van Damme P, Richardson WD, Robberecht W. Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis. Brain. 2013;136(Pt 2):471-482.  https://doi.org/10.1093/brain/aws339
  34. Kwong LK, Neumann M, Sampathu DM, Lee VM, Trojanowski JQ. TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. Acta Neuropathol. 2007;114(1):63-70.  https://doi.org/10.1007/s00401-007-0226-5
  35. Rutherford NJ, Zhang YJ, Baker M, Gass JM, Finch NA, Xu YF, Stewart H, Kelley BJ, Kuntz K, Crook RJ, Sreedharan J, Vance C, Sorenson E, Lippa C, Bigio EH, Geschwind DH, Knopman DS, Mitsumoto H, Petersen RC, Cashman NR, Hutton M, Shaw CE, Boylan KB, Boeve B, Graff-Radford NR, Wszolek ZK, Caselli RJ, Dickson DW, Mackenzie IR, Petrucelli L, Rademakers R. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet. 2008;4(9):e1000193. https://doi.org/10.1371/journal.pgen.1000193
  36. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, Baralle F, de Belleroche J, Mitchell JD, Leigh PN, Al-Chalabi A, Miller CC, Nicholson G, Shaw CE. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319(5870):1668-1672. https://doi.org/10.1126/science.1154584
  37. Lagier-Tourenne C, Polymenidou M, Hutt KR, Vu AQ, Baughn M, Huelga SC, Clutario KM, Ling SC, Liang TY, Mazur C, Wancewicz E, Kim AS, Watt A, Freier S, Hicks GG, Donohue JP, Shiue L, Bennett CF, Ravits J, Cleveland DW, Yeo GW. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat Neurosci. 2012;15(11):1488-1497. https://doi.org/10.1038/nn.3230
  38. Polymenidou M, Lagier-Tourenne C, Hutt KR, Bennett CF, Cleveland DW, Yeo GW. Misregulated RNA processing in amyotrophic lateral sclerosis. Brain Res. 2012;1462:3-15.  https://doi.org/10.1016/j.brainres.2012.02.059
  39. Sun Z, Diaz Z, Fang X, Hart MP, Chesi A, Shorter J, Gitler AD. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol. 2011;9(4):e1000614. https://doi.org/10.1371/journal.pbio.1000614
  40. Thompson VF, Victor RA, Morera AA, Moinpour M, Liu MN, Kisiel CC, Pickrel K, Springhower CE, Schwartz J. Transcription-dependent formation of nuclear granules containing FUS and RNA Pol II. Biochemistry. 2018;57(51):7021-7032. https://doi.org/10.1021/acs.biochem.8b01097
  41. De Santis R, Santini L, Colantoni A, Peruzzi G, de Turris V, Alfano V, Bozzoni I, Rosa A. FUS Mutant Human Motoneurons Display Altered Transcriptome and microRNA Pathways with Implications for ALS Pathogenesis. Stem Cell Rep. 2017;9:1450-1462. https://doi.org/10.1016/j.stemcr.2017.09.004
  42. Alexander EJ, Ghanbari Niaki A, Zhang T, Sarkar J, Liu Y, Nirujogi RS, Pandey A, Myong S, Wang J. Ubiquilin 2 modulates ALS/FTD-linked FUS-RNA complex dynamics and stress granule formation. Proc Natl Acad Sci USA. 2018;115(49):11485-11494. https://doi.org/10.1073/pnas.1811997115
  43. Wang H, Guo W, Mitra J, Hegde PM, Vandoorne T, Eckelmann BJ, Mitra S, Tomkinson AE, Van Den Bosch L, Hegde ML. Mutant FUS causes DNA ligation defects to inhibit oxidative damage repair in Amyotrophic Lateral Sclerosis. Nat Commun. 2018;9(1):3683. https://doi.org/10.1038/s41467-018-06111-6
  44. Delva L, Gallais I, Guillouf C, Denis N, Orvain C, Moreau-Gachelin F. Multiple functional domains of the oncoproteins Spi-1/PU.1 and TLS are involved in their opposite splicing effects in erythroleukemic cells. Oncogene. 2004;23(25):4389-4399. https://doi.org/10.1038/sj.onc.1207578
  45. Uranishi H, Tetsuka T, Yamashita M, Asamitsu K, Shimizu M, Itoh M, Okamoto T. Involvement of the pro-oncoprotein TLS (translocated in liposarcoma) in nuclear factor-kappa B p65-mediated transcription as a coactivator. J Biol Chem. 2001;276(16):13395-13401. https://doi.org/10.1074/jbc.m011176200
  46. Immanuel D, Zinszner H, Ron D. Association of SARFH (sarcoma-associated RNA-binding fly homolog) with regions of chromatin transcribed by RNA polymerase II. Mol Cell Biol. 1995;15(8):4562-4571. https://doi.org/10.1128/mcb.15.8.4562
  47. Shelkovnikova TA, Peters OM, Deykin AV, Connor-Robson N, Robinson H, Ustyugov AA, Bachurin SO, Ermolkevich TG, Goldman IL, Sadchikova ER, Kovrazhkina EA, Skvortsova VI, Ling SC, Da Cruz S, Parone PA, Buchman VL, Ninkina NN. Fused in sarcoma (FUS) protein lacking nuclear localization signal (NLS) and major RNA binding motifs triggers proteinopathy and severe motor phenotype in transgenic mice. J Biol Chem. 2013;288(35):25266-25274. https://doi.org/10.1074/jbc.M113.492017
  48. Robinson HK, Deykin AV, Bronovitsky EV, Ovchinnikov RK, Ustyugov AA, Shelkovnikova TA, Kukharsky MS, Ermolkevich TG, Goldman IL, Sadchikova ER, Kovrazhkina EA, Bachurin SO, Buchman VL, Ninkina NN. Early lethality and neuronal proteinopathy in mice expressing cytoplasm-targeted FUS that lacks the RNA recognition motif. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):402-409.  https://doi.org/10.3109/21678421.2015.1040994
  49. Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, Yang Y, Fecto F, Shi Y, Zhai H, Jiang H, Hirano M, Rampersaud E, Jansen GH, Donkervoort S, Bigio EH, Brooks BR, Ajroud K, Sufit RL, Haines JL, Mugnaini E, Pericak-Vance MA, Siddique T. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011;477(7363):211-215.  https://doi.org/10.1038/nature10353
  50. Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, Pestronk A, Whyte MP, Kimonis VE. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004;36(4):377-381.  https://doi.org/10.1038/ng1332
  51. Weihl CC, Miller SE, Hanson PI, Pestronk A. Transgenic expression of inclusion body myopathy associated mutant p97/VCP causes weakness and ubiquitinated protein inclusions in mice. Hum Mol Genet. 2007;16(8):919-928.  https://doi.org/10.1093/hmg/ddm037
  52. Nalbandian A, Nguyen C, Katheria V, Llewellyn KJ, Badadani M, Caiozzo V, Kimonis VE. Exercise training reverses skeletal muscle atrophy in an experimental model of VCP disease. PLoS One. 2013;8(10):e76187. https://doi.org/10.1371/journal.pone.0076187
  53. Chen X, Yazdani S, Piehl F, Magnusson PKE, Fang F. Polygenic link between blood lipids and amyotrophic lateral sclerosis. Neurobiol Aging. 2018;67:202.e1-202.e6.  https://doi.org/10.1016/j.neurobiolaging.2018.03.022
  54. Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R, Seilhean D, Hauw JJ, Lacomblez L, Loeffler JP, Meininger V. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70(13):1004-1009. https://doi.org/10.1212/01.wnl.0000285080.70324.27
  55. Huang R, Guo X, Chen X, Zheng Z, Wei Q, Cao B, Zeng Y, Shang H. The serum lipid profiles of amyotrophic lateral sclerosis patients: A study from south-west China and a meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):359-365.  https://doi.org/10.3109/21678421.2015.1047454
  56. Rafiq MK, Lee E, Bradburn M, McDermott CJ, Shaw PJ. Effect of lipid profile on prognosis in the patients with amyotrophic lateral sclerosis: Insights from the olesoxime clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):478-484.  https://doi.org/10.3109/21678421.2015.1062517
  57. Chiò A, Calvo A, Ilardi A, Cavallo E, Moglia C, Mutani R, Palmo A, Galletti R, Marinou K, Papetti L, Mora G. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology. 2009;73(20):1681-1685. https://doi.org/10.1212/wnl.0b013e3181c1df1e
  58. Henriques A, Blasco H, Fleury MC, Corcia P, Echaniz-Laguna A, Robelin L, Rudolf G, Lequeu T, Bergaentzle M, Gachet C, Pradat PF, Marchioni E, Andres CR, Tranchant C, Gonzalez De Aguilar JL, Loeffler JP. Blood Cell Palmitoleate-Palmitate Ratio Is an Independed Prognistic Factor for Amyotrophic Lateral Sclerosis. PLoS One. 2015;10(7):e0131512. https://doi.org/10.1371/journal.pone.0131512
  59. Borovik TE, Gribakin SG, Skvortsova VA, Semenova NN, Stepanova TN, Zvonkova NG. Long-chain polyunsaturated fatty acids and their role in children nourishment. Voprosy Sovremennoi Pediatrii. 2012;11(4):21-28. (In Russ.). https://doi.org/10.15690/vsp.v11i4.355
  60. Fitzgerald KC, O’Reilly ÉJ, Falcone GJ, McCullough ML, Park Y, Kolonel LN, Ascherio A. Dietary ω-3 polyunsaturated fatty acid intake and risk for amyotrophic lateral sclerosis. JAMA Neurol. 2014;71(9):1102-1110. https://doi.org/10.1001/jamaneurol.2014.1214
  61. Cacabelos D, Ayala V, Granado-Serrano AB, Jové M, Torres P, Boada J, Cabré R, Ramírez-Núñez O, Gonzalo H, Soler-Cantero A, Serrano JC, Bellmunt MJ, Romero MP, Motilva MJ, Nonaka T, Hasegawa M, Ferrer I, Pamplona R, Portero-Otín M. Interplay between TDP-43 and docosahexaenoic acid-related processes in amyotrophic lateral sclerosis. Neurobiol Dis. 2016;88:148-160.  https://doi.org/10.1016/j.nbd.2016.01.007
  62. Liu G, Fiala M, Mizwicki MT, Sayre J, Magpantay L, Siani A, Mahanian M, Chattopadhyay M, La Cava A, Wiedau-Pazos M. Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am J Neurodegener Dis. 2012;1(1):60-74. PMID: 22787561.
  63. Iłzecka J. Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients. Acta Neurol Scand. 2003;108(2):125-129.  https://doi.org/10.1034/j.1600-0404.2003.00102.x
  64. Miyagishi H, Kosuge Y, Takano A, Endo M, Nango H, Yamagata-Murayama S, Hirose D, Kano R, Tanaka Y, Ishige K, Ito Y. Increased Expression of 15-Hydroxyprostaglandin Dehydrogenase in Spinal Astrocytes During Disease Progression in a Model of Amyotrophic Lateral Sclerosis. Cell Mol Neurobiol. 2017;37(3):445-452.  https://doi.org/10.1007/s10571-016-0377-9
  65. Yip PK, Pizzasegola C, Gladman S, Biggio ML, Marino M, Jayasinghe M, Ullah F, Dyall SC, Malaspina A, Bendotti C, Michael-Titus A. The omega-3 fatty acid eicosapentaenoic acid accelerates disease progression in a model of amyotrophic lateral sclerosis. PLoS One. 2013;8(4):e61626. https://doi.org/10.1371/journal.pone.0061626
  66. Diaz-Amarilla P, Miquel E, Trostchansky A, Trias E, Ferreira AM, Freeman BA, Cassina P, Barbeito L, Vargas MR, Rubbo H. Electrophilic nitro-fatty acids prevent astrocyte-mediated toxicity to motor neurons in a cell model of familial amyotrophic lateral sclerosis via nuclear factor erythroid 2-related factor activation. Free Radic Biol Med. 2016;95:112-120.  https://doi.org/10.1016/j.freeradbiomed.2016.03.013
  67. Rubbo H. Nitro-fatty acids: novel anti-inflammatory lipid mediators. Braz J Med Biol Res. 2013;46(9):728-734.  https://doi.org/10.1590/1414-431X20133202
  68. Trostchansky A, Mastrogiovanni M, Miquel E, Rodríguez-Bottero S, Martínez-Palma L, Cassina P, Rubbo H. Profile of Arachidonic Acid-Derived Inflammatory Markers and Its Modulation by Nitro-Oleic Acid in an Inherited Model of Amyotrophic Lateral Scleros. Front Mol Neurosci. 2018;11:131.  https://doi.org/10.3389/fnmol.2018.00131
  69. Veldink JH, Kalmijn S, Groeneveld GJ, Wunderink W, Koster A, de Vries JH, van der Luyt J, Wokke JH, Van den Berg LH. Intake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2007;78(4):367-371.  https://doi.org/10.1136/jnnp.2005.083378
  70. Zhao W, Varghese M, Vempati P, Dzhun A, Cheng A, Wang J, Lange D, Bilski A, Faravelli I, Pasinetti GM. Caprylic Triglyceride as a Novel Therapeutic Approach to Effectively Improve the Performance and Attenuate the Symptoms Due to the Motor Neuron Loss in ALS Disease. PLoS One. 2012;7(11):e49191. https://doi.org/10.1371/journal.pone.0049191
  71. Wuolikainen A, Acimovic J, Lövgren-Sandblom A, Parini P, Andersen PM, Björkhem I. Cholesterol, Oxysterol, Triglyceride, and Coenzyme Q Homeostasis in ALS. Evidence against the Hypothesis That Elevated 27-Hydroxycholesterol. Is a Pathogenic Factor PLoS One. 2014;9(11):e113619. https://doi.org/10.1371/journal.pone.0113619
  72. Dorst J, Kühnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol. 2011;258(4):613-617.  https://doi.org/10.1007/s00415-010-5805-z
  73. Blasco H, Veyrat-Durebex C, Bocca C, Patin F, Vourc’h P, Kouassi Nzoughet J, Lenaers G, Andres CR, Simard G, Corcia P, Reynier P. Lipidomics Reveals Cerebrospinal-Fluid Signatures of ALS. Sci Rep. 2017;7(1):17652. https://doi.org/10.1038/s41598-017-17389-9
  74. Alessenko AV. The potential role of sphingolipids in neuropathogenesis of Alzheiner’s disease. Biomedicinskaya Kchimia. 2013;59(1):25-50. (In Russ.). https://doi.org/10.18097/pbmc20135901025
  75. Arima H, Omura T, Hayasaka T, Masaki N, Hanada M, Xu D, Banno T, Kobayashi K, Takeuchi H, Kadomatsu K, Matsuyama Y, Setou M. Reductions of docosahexaenoic acid-containing phosphatidylcholine levels in the anterior horn of an ALS mouse model. Neuroscience. 2015;297:127-136.  https://doi.org/10.1016/j.neuroscience.2015.03.060
  76. Sutedja NA, van der Schouw YT, Fischer K, Sizoo EM, Huisman MH, Veldink JH, Van den Berg LH. Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2011;82(6):638-642.  https://doi.org/10.1136/jnnp.2010.236752
  77. Russell DW, Halford RW, Ramirez DM, Shah R, Kotti T. Cholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brain. Annu Rev Biochem. 2009;78:1017-1040. https://doi.org/10.1146/annurev.biochem.78.072407.103859
  78. Poirier J, Baccichet A, Dea D, Gauthier S. Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience. 1993;55(1):81-90.  https://doi.org/10.1016/0306-4522(93)90456-p
  79. Mukhutdinova KA, Kasimov MR, Giniatullin AR, Zakyrjanova GF, Petrov AM. 24S-hydroxycholesterol suppresses neuromuscular transmission in SOD1 (G93A) mice: A possible role of NO and lipid rafts. Mol Cell Neurosci. 2018;88:308-318.  https://doi.org/10.1016/j.mcn.2018.03.006
  80. Vejux A, Namsi T, Nury T, Moreau T, Lizard G. Biomarkers of amyotrophic lateral sclerosis: current status and interest of oxysterols. Front Mol Neurosci. 2018;11:12.  https://doi.org/10.3389/fnmol.2018.00012
  81. Diekstra FP, Saris, Christiaan GJ, Rheenen W, Franke L, Ritsert CJ, van Es MA, van Vught PWJ, Blauw HM, Groen EJN, Horvath S, Estrada K, Rivadeneira F, Hofman A, Uitterlinden AG, Robberecht W, Andersen PM, Melki J, Meininger V, Hardiman O, Landers JE, Brown RHJr, Shatunov A, Shaw CE, P. Leigh N, Al-Chalabi A,. Ophoff RA, van den Berg LH Veldink JH. Mapping of Gene Expression Reveals CYP27A1 as a Susceptibility Gene for Sporadic ALS. PLoS One. 2012;7(4):e35333. https://doi.org/10.1371/journal.pone.0035333
  82. Antonini A, Caioli S, Saba L, Vindigni G, Biocca S, Canu N, Zona C. Membrane cholesterol depletion in cortical neurons highlights altered NMDA receptor functionality in a mouse model of amyotrophic lateral sclerosis. Biochim Biophys Acta. 2018;1864(2):509-519.  https://doi.org/10.1016/j.bbadis.2017.11.008
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.